WallStreetZen

NASDAQ: AZN
Astrazeneca Plc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

AZN past earnings growth

How has AZN's earnings growth performed historically?
Company
75.61%
Industry
14.79%
Market
102.72%
AZN's earnings have grown slower (10.48% per year) than the US Drug Manufacturers - General industry average (14.81%)
Performance
AZN's earnings have grown slower (10.48% per year) than the US market average (27.52%)
Performance
AZN's earnings growth is accelerating - its growth over the last year (75.61%) is above its 5-year compound annual rate (10.48%)
Performance

AZN past revenue growth

How has AZN's revenue growth performed historically?
Company
14.9%
Industry
13.32%
Market
36.32%
AZN's revenue has grown slower (4.18% per year) than the US Drug Manufacturers - General industry average (5.13%)
Performance
AZN's revenue has grown slower (4.18% per year) than the US market average (17.66%)
Performance
AZN's revenue growth is accelerating - its growth over the last year (14.9%) is above its 5-year compound annual rate (4.18%)
Performance

AZN earnings and revenue history

Current Revenue
$29.5B
Current Earnings
$3.8B
Current Profit Margin
12.8%
AZN's has not demonstrated consistent long-term earnings growth over the past 10 years (-50.68%)
Performance

AZN Return on equity

Current Company
26%
Current Industry
19.5%
Current Market
39.8%
AZN's Return on Equity (26%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

AZN Return on assets

Current Company
5.6%
Current Industry
6.5%
Current Market
12.2%
AZN is generating lower Return on Assets (5.6%) than the US Drug Manufacturers - General industry average (7.27%)
Performance

AZN Return on capital employed

Current Company
11.02%
Current Industry
10.5%
AZN has gotten more efficient at generating Return on Capital (11.02%) compared to 3 years ago (7.65%)
Performance

Astrazeneca Earnings & Revenue FAQ

What were AZN's earnings last quarter?

Astrazeneca (NASDAQ: AZN) reported Q2 2021 earnings per share (EPS) of $0.21, up 27.59% year over year. Total Astrazeneca earnings for the quarter were $550.00 million. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.29.

What was AZN's earnings growth in the past year?

As of Q3 2021, Astrazeneca's earnings has grown 75.61% year over year. This is 60.82 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of 14.79%. Astrazeneca's earnings in the past year totalled $3.77 billion.

What was AZN's revenue last quarter?

Astrazeneca (NASDAQ: AZN) reported Q2 2021 revenue of $8.22 billion up 31% year over year. In the same quarter last year, Astrazeneca's revenue was $6.28 billion.

What was AZN's revenue growth in the past year?

As of Q3 2021, Astrazeneca's revenue has grown 14.9% year over year. This is 1.58 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 13.32%. Astrazeneca's revenue in the past year totalled $29.53 billion.
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.